

Filed by Exact Sciences Corporation  
pursuant to Rule 425 under the Securities Act of 1933  
and deemed filed pursuant to Rule 14a-12  
under the Securities Exchange Act of 1934

Filer: Exact Sciences Corporation  
Subject Company: Genomic Health, Inc.  
SEC File No.: 000-51541

Date: July 29, 2019

**The following is available at [www.leadingcancerdiagnostics.com](http://www.leadingcancerdiagnostics.com):**

Exact Sciences + Genomic Health

## COMBINING TO CREATE A LEADING GLOBAL CANCER DIAGNOSTICS COMPANY

[VIEW INFOGRAPHIC](#)



**Provides platform for growth** by combining two of the strongest brands in cancer diagnostics, ColoGuard® and OncoType DX®, into one entity



**Forms best-in-class R&D and clinical organization** with enhanced scale, a robust evidence generation engine, complemented by proven regulatory expertise, and key relationships with oncologists



**Provides global infrastructure** and commercial presence in 90+ countries with expanded reach across primary care, oncology, OB/GYN, gastroenterology, and urology to support growth of existing and future cancer tests



**Enhances financial strength** with expected pro forma revenue of \$1.6 billion, and gross profit of \$0.2 billion in 2020

### CREATING A HIGH-GROWTH LEADER TO IMPROVE WHEN CANCER IS DETECTED AND HOW IT IS TREATED

Exact Sciences and Genomic Health have entered into a definitive agreement under which Exact Sciences will combine with Genomic Health for \$7000 per share in a cash and stock transaction valued at \$2.8 billion.

Together, Exact Sciences and Genomic Health will create a leading global cancer diagnostics company. Through ColoGuard® and OncoType DX®, the combined leading brands, respectively will continue to help detect colorectal cancer and inform treatment decisions in colorectal, breast and prostate cancer, which collectively represent approximately 40% of all solid tumor incidences. By joining the teams at Exact Sciences and Genomic Health, we are forming a best-in-class R&D and clinical organization with enhanced scale and scope, and establishing the global infrastructure to accelerate the availability of new innovative cancer diagnostics to more patients. Further, the combined company will have a commercial presence in more than 90 countries and expanded reach across primary care, oncology, OB/GYN,





2019 Annual Meeting of Stockholders, which was held with the SEC on April 30, 2019, and Drug Science's Current Report on Form 8-K, which was filed with the SEC on July 26, 2019. Information about scientific, health practices and executive officer's activities in Canada's health policy statement for its 2019 Annual Meeting of Stockholders, which was filed with the SEC on April 25, 2019, and Canada's Health Report on Form 10-K for the year ended December 31, 2019, which was filed with the SEC on February 26, 2020. Other information regarding the participants in the policy statement and a description of the plan and related matters, by security holding or otherwise, will be provided to the appropriate customers, the policy, information and other relevant materials to the extent the plan, including the proposed structure, what they believe would be the best course of action to maintain and other matters should not be using statement prepared to comply when it becomes available to the making any other or treatment decisions. No registration of the report of these documents from Drug Science or Canada's health is indicated above.

**No Offer or Solicitation**

This communication does not constitute an offer to buy or sell securities, nor does it constitute an offer to purchase or sell securities in any jurisdiction in which such offer or sale would be unlawful under the securities laws of any jurisdiction. Under the securities laws of any jurisdiction, the offering of securities may be made except by means of a prospectus meeting the requirements of Section 11 of the U.S. Securities Act of 1933, as amended.











